Skip to main content

Table 3 Summary of studies reporting assessment of EGFR/KRAS or EGFR/KRAS/other molecular markers

From: Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

Reference Patient demographics: Description of matched pairs Synchronous/metachronous/metastases, n:n Molecular marker assessment technique Mutation frequency,c n/N (%) Concordance, n/N (%)
(i) Median age (range), years N Tumour sample storage form Primary Metastatic: n  
(ii) Gender, n/N (%) male Histological subtype: n Time between primary and metastatic tumour sample collection b
(iii) Ethnicity [countrya]  
(iv) Smoking status, n/N (%)
Assessment of EGFR/KRAS molecular markers
 Han et al. [49] (i) 60 (44–76) 22 Snap frozen Lung Lymph node N/A Direct sequencing [EGFR] [EGFR]
(ii) 12/22 (55) ADC: 15 N/A 7/22 (32) vs 6/22 (27) 21/22 (95)
(iii) [China] SSC: 7 [KRAS] [KRAS]
(iv) Never-smoker: 6/22 (27); former smoker: 5/22 (23); current smoker: 11/22 (50) 2/22 (9) vs 1/22 (5) 21/22 (95)
 Han et al. [29] (i) 66 (40–94) 37 FFPE Lung Pleural effusion: 12 32:5 Direct sequencing [EGFR] [EGFR]
(ii) 20/37 (54.1) ADC: 37 Pleura: 9 N/A   18/37 (49) vs 16/37 (43) 30/37 (81)
(iii) [Korea] Brain: 5 [KRAS] [KRAS]
(iv) Never-smoker: 18/37 (48.6); former and current smoker: 16/37 (43.2) Lymph node: 3 1/37 (3) vs 2/37 (5) 36/37 (97)
Lung: 2
Soft tissue: 2
Adrenal gland: 1
Pericardial effusion: 1
Pericardium: 1
Ovary: 1
 Kalikaki et al. [46] (i) 55 (41–70) 25 FFPE Lung Lung: 9 0:25 Direct sequencing [EGFR] [EGFR]
(ii) 22/25 (88) ADC: 18 Thoracic wall: 5 Median time between resection of primary and corresponding metastatic tumours: 30 months (range 4–143) 5/25 (20) vs 3/25 (12) 18/25 (72)
(iii) Caucasian SSC: 2 Adrenal gland: 4 [KRAS] [KRAS]
(iv) Never-smoker: 3/25 (12); active or former smoker: 22/25 (88) ADC/BAC: 2 Brain: 3 5/25 (20) vs 5/25 (20) 19/25 (76)
LCC: 2 Bone: 2
GCC: 1 Skin: 1
Liver: 1
 Munfus-McCray et al. [48] (i) 56.3 (51–80) 9 FFPE Lung Brain: 3 N/A [EGFR] Bidirectional DNA sequencing [EGFR] [EGFR]
(ii) N/A (66.7) Lymph node: 3 N/A [KRAS] Pyrosequencing following microdissection of tumour tissue 3/9 (33) vs 2/9 (22) 8/9 (89)
(iii) [USA] Pleura: 1 [KRAS] [KRAS]
(iv) Never-smoker: 4/9 (N/A); current and former smoker: 4/9 (N/A) Knee: 1 1/9 (11) vs 2/9 (22) 8/9 (89)
Contralateral lung: 1
 Sun et al. [32] (i) [Mean] 58 (32–77) 80 FFPE Lung Lymph nodes 80:0 Direct sequencing [EGFR] [EGFR]
(ii) 50/80 (62.5) ADC: 39 [Concurrent] 21/80 (26) vs 26/80 (33) 73/80 (91)
(iii) Chinese SSC: 31 [KRAS] [KRAS]
(iv) Never-smoker: 31/80 (38.75); ever-smoker: 49/80 (61.25) Adenosquamous carcinoma: 6 1/80 (1) vs 7/80 (9) 74/80 (93)
LCC: 4
Assessment of EGFR/KRAS/BRAF molecular markers
 Schmid et al. [47] (i) 62 (42–81) 96 FFPE Lung Locoregional lymph node N/A Direct bidirectional sequencing [EGFR] [EGFR]
(ii) 58/96 (60.4) N/A 4/96 (4) vs 4/96 (4) 90/96 (94)
(iii) Caucasian [Austria] [KRAS] [KRAS]
(iv) Never-smoker: 22/96 (23); current smoker: 60/96 (63); former smoker: 14/96 (15) 28/96 (29) vs 20/96 (21) 71/96 (74)
[BRAF] [BRAF]
2/96 (2) vs 0/96 (0) 94/96 (98)
Assessment of EGFR/KRAS/p53 molecular markers
 Takahashi et al. [61] (i) [At diagnosis] (43–79) 8 FFPE Lung Brain: 7 N/A High resolution SNP array (following laser capture microdissection in some cases) [EGFR] N/A
(ii) 5 ADC: 3 Lymph node: 3 Time between resection of primary and corresponding metastatic tumours (range): 0–64 months (not reported for 2 sample pairs) 3/8 (38) vs 3/8 (38)
(iii) [Japan] SSC: 1 Liver: 2 [p53]
(iv) Never-smoker: 3; ever-smoker: 5 LCC: 1 Pulmonary: 1 7/8 (88) vs 7/8 (88)
SCC: 3 Pleural: 1 [KRAS]
0/8 (0) vs 0/8 (0)
  1. ADC Adenocarcinoma, BAC Bronchioloalveolar carcinoma, BRAF Murine sarcoma viral oncogene homolog B1, DNA Deoxyribonucleic acid, EGFR Epidermal growth factor receptor, FFPE Formalin-fixed paraffin-embedded, GCC Giant cell carcinoma, KRAS Kirsten rat sarcoma viral oncogenes homolog, LCC Large cell carcinoma, N/A Not available, SCC Small cell carcinoma, SNP Single nucleotide polymorphism, SSC Squamous cell carcinoma
  2. aAs described in study (country from which samples were taken from)
  3. bConcurrent or non-concurrent if time not specified
  4. cPrimary vs metastatic tumour samples